| 徐柯贝,胡婉湘,蓝胜勇,唐秀文,徐 鹏.胶质母细胞瘤组织转录因子叉头框 C1、D1的表达及其临床意义[J].,2023,(20):3913-3917 |
| 胶质母细胞瘤组织转录因子叉头框 C1、D1的表达及其临床意义 |
| Expression and Clinical Significance of Transcription Factors C1 and D1 in Transcription Factor of Glioblastoma Tissue |
| 投稿时间：2023-03-24 修订日期：2023-04-20 |
| DOI：10.13241/j.cnki.pmb.2023.20.023 |
| 中文关键词: 胶质母细胞瘤 FOXC1 FOXD1 预后 临床意义 |
| 英文关键词: Glioblastoma FOXC1 FOXD1 Prognosis Clinical significance |
| 基金项目:广西壮族自治区卫生和计划生育委员会计划课题（Z2015319） |
|
| 摘要点击次数: 383 |
| 全文下载次数: 294 |
| 中文摘要: |
| 摘要 目的：研究胶质母细胞瘤（GBM）组织转录因子叉头框C1（FOXC1）、叉头框D1（FOXD1）的表达及临床意义。方法：选取自2018年2月至2021年10月期间广西壮族自治区人民医院诊治的98例GBM患者，取胶质瘤组织作为研究样本（GBM组），以同期因颅脑损伤接受内减压术切除的40例患者，取正常脑组织样本作为对照组。采用免疫组化法检测GBM组及对照组中FOXC1、FOXD1的表达。Kaplan-Meier生存分析（Log-Rank检验）不同FOXC1，FOXD1表达的GBM患者生存预后的差异。单因素及多因素Cox比例回归风险模型分析影响GBM患者生存预后的因素。结果：GBM组中FOXC1，FOXD1蛋白主要定位于细胞核。GBM组中FOXC1，FOXD1蛋白阳性表达率为67.35%，65.31%，明显高于对照组的12.50%，10.00%（均P＜0.05）。GBM 组中FOXC1，FOXD1的表达与肿瘤直径及WHO中枢神经系统肿瘤分级有关（P＜0.05）。随访1年，死亡60例，1年总生存率为38.78%。FOXC1阳性组和FOXC1阴性组1年总生存率分别为27.27%，62.50%。FOXD1阳性组和FOXD1阴性组1年总生存率分别为26.56%，61.76%。Kaplan-Meier生存分析显示，FOXC1阳性组累积总生存率明显低于FOXC1阴性组，FOXD1阳性组累积总生存率明显低于FOXD1阴性组（均P＜0.05）。经多因素Cox回归分析结果显示术前KPS评分<80分、WHO中枢神经系统肿瘤分级Ⅲ～Ⅳ级、无术后放疗、无术后替莫唑胺化疗、FOXC1阳性、FOXD1阳性是GBM患者不良生存预后的独立危险因素。结论：GBM组织FOXC1，FOXD1阳性表达升高，两者与肿瘤直径及WHO中枢神经系统肿瘤分级有关，是GBM患者不良预后的独立危险因素。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression and clinical significance of transcription factors forkhead box C1 (FOXC1) and forkhead box D1 (FOXD1) in transcription factor of glioblastoma (GBM) tissue. Methods: 98 cases of GBM who were diagnosed and treated in The People's Hospital of Guangxi Zhuang Autonomous Region from February 2018 to October 2021 were selected ,and glioma tissue was taken as the study sample (GBM group) , 40 patients who underwent internal decompression surgery for craniocerebral injury during the same period were selected , and normal brain tissue samples were taken as the control group. Immunohistochemistry was used to detect the expression of FOXC1 and FOXD1 in GBM group and control group. Kaplan Meier survival analysis (Log Rank test) were used to analyze the differences in survival outcomes among GBM patients with different FOXC1 and FOXD1 expression. Univariate and multivariate Cox proportional regression risk models were used to analyze factors affecting the survival and prognosis of GBM patients. Results: In GBM group, FOXC1 and FOXD1 proteins were mainly localized in the nucleus. The positive expression rates of FOXC1 and FOXD1 in GBM group were 67.35%, 65.31%, which were significantly higher than 12.50%, 10.00% in control group(all P<0.05). The expression of FOXC1 and FOXD1 in the GBM group is related to tumor diameter and WHO central nervous system tumor grading(P<0.05). Follow up for 1 year, 60 cases died, with a 1-year overall survival rate of 38.78%. The overall one-year survival rates in the FOXC1 positive and negative groups were 27.27% and 62.50%, respectively. The overall one-year survival rates in the FOXD1 positive and negative groups were 26.56% and 61.76% , respectively. Kaplan Meier survival analysis showed that the cumulative overall survival rate of the FOXC1 positive group was significantly lower than that of the FOXC1 negative group, and the cumulative overall survival rate of the FOXD1 positive group was significantly lower than that of the FOXD1 negative group (all P<0.05). The results of multi factor Cox regression analysis show that KPS score<80 before operation, WHO Central Nervous System Tumor Grading III-IV, no postoperative radiotherapy, no postoperative Temozolomide chemotherapy, FOXC1 positive, FOXD1 positive are independent risk factors for poor survival and prognosis of GBM patients. Conclusion: The expression of FOXC1 and FOXD1 in GBM tissue are elevated, both of them are associated with tumor diameter and WHO central nervous system tumor grading and are independent risk factor for poor prognosis in GBM patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
